Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Shayne Taback is active.

Publication


Featured researches published by Shayne Taback.


Nature | 2007

A genome-wide association study identifies KIAA0350 as a type 1 diabetes gene.

Hakon Hakonarson; Struan F. A. Grant; Jonathan P. Bradfield; Luc Marchand; Cecilia E. Kim; Joseph T. Glessner; Rosemarie Grabs; Tracy Casalunovo; Shayne Taback; Edward C. Frackelton; Margaret L. Lawson; Luke J. Robinson; Robert Skraban; Yang Lu; Rosetta M. Chiavacci; Charles A. Stanley; Susan E. Kirsch; Eric Rappaport; Jordan S. Orange; Dimitri Monos; Marcella Devoto; Hui Qi Qu; Constantin Polychronakos

Type 1 diabetes (T1D) in children results from autoimmune destruction of pancreatic beta cells, leading to insufficient production of insulin. A number of genetic determinants of T1D have already been established through candidate gene studies, primarily within the major histocompatibility complex but also within other loci. To identify new genetic factors that increase the risk of T1D, we performed a genome-wide association study in a large paediatric cohort of European descent. In addition to confirming previously identified loci, we found that T1D was significantly associated with variation within a 233-kb linkage disequilibrium block on chromosome 16p13. This region contains KIAA0350, the gene product of which is predicted to be a sugar-binding, C-type lectin. Three common non-coding variants of the gene (rs2903692, rs725613 and rs17673553) in strong linkage disequilibrium reached genome-wide significance for association with T1D. A subsequent transmission disequilibrium test replication study in an independent cohort confirmed the association. These results indicate that KIAA0350 might be involved in the pathogenesis of T1D and demonstrate the utility of the genome-wide association approach in the identification of previously unsuspected genetic determinants of complex traits.


Diabetes | 2008

A Novel Susceptibility Locus for Type 1 Diabetes on Chr12q13 Identified by a Genome-Wide Association Study

Hakon Hakonarson; Hui Qi Qu; Jonathan P. Bradfield; Luc Marchand; Cecilia E. Kim; Joseph T. Glessner; Rosemarie Grabs; Tracy Casalunovo; Shayne Taback; Edward C. Frackelton; Andrew W. Eckert; Kiran Annaiah; Margaret L. Lawson; F. George Otieno; Erin Santa; Julie L. Shaner; Ryan M. Smith; Chioma C. Onyiah; Robert Skraban; Rosetta M. Chiavacci; Luke J. Robinson; Charles A. Stanley; Susan E. Kirsch; Marcella Devoto; Dimitri Monos; Struan F. A. Grant; Constantin Polychronakos

OBJECTIVE—In stage 1 of our genome-wide association (GWA) study for type 1 diabetes, one locus at 16p13 was detected (P = 1.03 × 10−10) and confirmed in two additional cohorts. Here we describe the results of testing, in these additional cohorts, 23 loci that were next in rank of statistical significance. RESEARCH DESIGN AND METHODS—Two independent cohorts were studied. The Type 1 Diabetes Genetics Consortium replication cohort consisted of 549 families with at least one child diagnosed with diabetes (946 total affected) and DNA from both parents. The Canadian replication cohort consisted of 364 nuclear family trios with one type 1 diabetes–affected offspring and two parents (1,092 individuals). RESULTS—One locus at 12q13, with the highest statistical significance among the 23, was confirmed. It involves type 1 diabetes association with the minor allele of rs1701704 (P = 9.13 × 10−10, OR 1.25 [95% CI 1.12–1.40]). CONCLUSIONS—We have discovered a type 1 diabetes locus at 12q13 that is replicated in an independent cohort of type 1 diabetic patients and confers a type 1 diabetes risk comparable with that of the 16p13 locus we recently reported. These two loci are identical to two loci identified by the whole-genome association study of the Wellcome Trust Case-Control Consortium, a parallel independent discovery that adds further support to the validity of the GWA approach.


Diabetes | 2009

Follow-up analysis of genome-wide association data identifies novel loci for type 1 diabetes.

Struan F. A. Grant; Hui Qi Qu; Jonathan P. Bradfield; Luc Marchand; Cecilia E. Kim; Joseph T. Glessner; Rosemarie Grabs; Shayne Taback; Edward C. Frackelton; Andrew W. Eckert; Kiran Annaiah; Margaret L. Lawson; F. George Otieno; Erin Santa; Julie L. Shaner; Ryan M. Smith; Robert Skraban; Marcin Imielinski; Rosetta M. Chiavacci; Robert W. Grundmeier; Charles A. Stanley; Susan E. Kirsch; Daryl Waggott; Andrew D. Paterson; Dimitri Monos; Constantin Polychronakos; Hakon Hakonarson

OBJECTIVE—Two recent genome-wide association (GWA) studies have revealed novel loci for type 1 diabetes, a common multifactorial disease with a strong genetic component. To fully utilize the GWA data that we had obtained by genotyping 563 type 1 diabetes probands and 1,146 control subjects, as well as 483 case subject–parent trios, using the Illumina HumanHap550 BeadChip, we designed a full stage 2 study to capture other possible association signals. RESEARCH DESIGN AND METHODS—From our existing datasets, we selected 982 markers with P < 0.05 in both GWA cohorts. Genotyping these in an independent set of 636 nuclear families with 974 affected offspring revealed 75 markers that also had P < 0.05 in this third cohort. Among these, six single nucleotide polymorphisms in five novel loci also had P < 0.05 in the Wellcome Trust Case-Control Consortium dataset and were further tested in 1,303 type 1 diabetes probands from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) plus 1,673 control subjects. RESULTS—Two markers (rs9976767 and rs3757247) remained significant after adjusting for the number of tests in this last cohort; they reside in UBASH3A (OR 1.16; combined P = 2.33 × 10−8) and BACH2 (1.13; combined P = 1.25 × 10−6). CONCLUSIONS—Evaluation of a large number of statistical GWA candidates in several independent cohorts has revealed additional loci that are associated with type 1 diabetes. The two genes at these respective loci, UBASH3A and BACH2, are both biologically relevant to autoimmunity.


Arthritis Care and Research | 2010

Prevalent Vertebral Fractures among Children Initiating Glucocorticoid Therapy for the Treatment of Rheumatic Disorders

Adam M. Huber; Isabelle Gaboury; David A. Cabral; Bianca Lang; Andy Ni; David Stephure; Shayne Taback; Peter B. Dent; Janet Ellsworth; Claire LeBlanc; Claire Saint-Cyr; Rosie Scuccimarri; John Hay; Brian Lentle; M. Matzinger; Nazih Shenouda; David Moher; Frank Rauch; Kerry Siminoski; Leanne M. Ward

Vertebral fractures are an under‐recognized problem in children with inflammatory disorders. We studied spine health among 134 children (87 girls) with rheumatic conditions (median age 10 years) within 30 days of initiating glucocorticoid therapy.


Arthritis Care and Research | 2012

Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: a national observational study.

Celia Rodd; Bianca Lang; Timothy Ramsay; Nathalie Alos; Adam M. Huber; David A. Cabral; Rosie Scuccimarri; Paivi Miettunen; J. Roth; Stephanie A. Atkinson; Robert Couch; Elizabeth A. Cummings; Peter B. Dent; Janet Ellsworth; John Hay; Kristin Houghton; Roman Jurencak; Maggie Larché; Claire LeBlanc; Kiem Oen; Claire Saint-Cyr; Robert Stein; David Stephure; Shayne Taback; Brian Lentle; M. Matzinger; Nazih Shenouda; David Moher; Frank Rauch; Kerry Siminoski

To determine the frequency of incident vertebral fractures (IVF) 12 months after glucocorticoid (GC) initiation in children with rheumatic diseases and to identify children at higher risk.


Journal of Clinical Oncology | 2012

High Incidence of Vertebral Fractures in Children With Acute Lymphoblastic Leukemia 12 Months After the Initiation of Therapy

Nathalie Alos; Ronald Grant; Timothy Ramsay; Jacqueline Halton; Elizabeth A. Cummings; Paivi Miettunen; Sharon Abish; Stephanie A. Atkinson; Ronald D. Barr; David A. Cabral; Elizabeth Cairney; Robert B. Couch; David Dix; Conrad V. Fernandez; John Hay; Sara J. Israels; Caroline Laverdière; Brian Lentle; Victor Lewis; M. Matzinger; Celia Rodd; Nazih Shenouda; Robert Stein; David Stephure; Shayne Taback; Beverly Wilson; Kathryn Williams; Frank Rauch; Kerry Siminoski; Leanne M. Ward

PURPOSE Vertebral fractures due to osteoporosis are a potential complication of childhood acute lymphoblastic leukemia (ALL). To date, the incidence of vertebral fractures during ALL treatment has not been reported. PATIENT AND METHODS We prospectively evaluated 155 children with ALL during the first 12 months of leukemia therapy. Lateral thoracolumbar spine radiographs were obtained at baseline and 12 months. Vertebral bodies were assessed for incident vertebral fractures using the Genant semiquantitative method, and relevant clinical indices such as spine bone mineral density (BMD), back pain, and the presence of vertebral fractures at baseline were analyzed for association with incident vertebral fractures. RESULTS Of the 155 children, 25 (16%; 95% CI, 11% to 23%) had a total of 61 incident vertebral fractures, of which 32 (52%) were moderate or severe. Thirteen (52%) of the 25 children with incident vertebral fractures also had fractures at baseline. Vertebral fractures at baseline increased the odds of an incident fracture at 12 months by an odds ratio of 7.3 (95% CI, 2.3 to 23.1; P = .001). In addition, for every one standard deviation reduction in spine BMD Z-score at baseline, there was 1.8-fold increased odds of incident vertebral fracture at 12 months (95% CI, 1.2 to 2.7; P = .006). CONCLUSION Children with ALL have a high incidence of vertebral fractures after 12 months of chemotherapy, and the presence of vertebral fractures and reductions in spine BMD Z-scores at baseline are highly associated clinical features.


Paediatric and Perinatal Epidemiology | 2013

Cohort Profile: The Maternal-Infant Research on Environmental Chemicals Research Platform

Tye E. Arbuckle; William D. Fraser; Mandy Fisher; Karelyn Davis; Chun Lei Liang; Nicole Lupien; Stéphanie Bastien; M.P. Vélez; Peter von Dadelszen; Denise G. Hemmings; Jingwei Wang; Michael Helewa; Shayne Taback; Mathew Sermer; Warren G. Foster; Greg Ross; Paul Fredette; Graeme N. Smith; Mark Walker; Roberta Shear; Linda Dodds; Adrienne S. Ettinger; Jean-Philippe Weber; Monique D'Amour; Melissa Legrand; Premkumari Kumarathasan; Renaud Vincent; Zhong-Cheng Luo; Robert W. Platt; Grant Mitchell

BACKGROUND The Maternal-Infant Research on Environmental Chemicals (MIREC) Study was established to obtain Canadian biomonitoring data for pregnant women and their infants, and to examine potential adverse health effects of prenatal exposure to priority environmental chemicals on pregnancy and infant health. METHODS Women were recruited during the first trimester from 10 sites across Canada and were followed through delivery. Questionnaires were administered during pregnancy and post-delivery to collect information on demographics, occupation, life style, medical history, environmental exposures and diet. Information on the pregnancy and the infant was abstracted from medical charts. Maternal blood, urine, hair and breast milk, as well as cord blood and infant meconium, were collected and analysed for an extensive list of environmental biomarkers and nutrients. Additional biospecimens were stored in the studys Biobank. The MIREC Research Platform encompasses the main cohort study, the Biobank and follow-up studies. RESULTS Of the 8716 women approached at early prenatal clinics, 5108 were eligible and 2001 agreed to participate (39%). MIREC participants tended to smoke less (5.9% vs. 10.5%), be older (mean 32.2 vs. 29.4 years) and have a higher education (62.3% vs. 35.1% with a university degree) than women giving birth in Canada. CONCLUSIONS The MIREC Study, while smaller in number of participants than several of the international cohort studies, has one of the most comprehensive datasets on prenatal exposure to multiple environmental chemicals. The biomonitoring data and biological specimen bank will make this research platform a significant resource for examining potential adverse health effects of prenatal exposure to environmental chemicals.


The American Journal of Gastroenterology | 2003

Bone density in a population-based cohort of premenopausal adult women with early onset inflammatory bowel disease.

Charles N. Bernstein; William D. Leslie; Shayne Taback

Abstract Objective We aimed to determine the bone mineral density (BMD) using dual energy x-ray absorptiometry in a population-based sample of women with inflammatory bowel disease who were diagnosed before age 20 yr and who are currently premenopausal and less than 45 yr. Methods The University of Manitoba Inflammatory Bowel Disease Epidemiology Research Registry was accessed to find eligible women. Of 171 eligible subjects, 82 agreed to participate, and 70 appeared for dual energy x-ray absorptiometry. All subjects completed demographic, clinical, and lifestyle questionnaires and underwent dual energy x-ray absorptiometry with analyses for both areal and volumetric BMD. Results The mean areal T scores at the lumbar spine, femoral neck, total hip, and total body were −0.14 ± 1.05, −0.15 ± 1.04, −0.25 ± 1.17, and +0.09 ± 1.04, respectively. Forty-five subjects had normal BMD, and 25 had a T score Conclusions In a population-based sample of women diagnosed with IBD before 20 yr of age and who are currently premenopausal, their average BMD is normal and the prevalence of osteoporosis is very low. Despite the potential for children with IBD to develop osteoporosis, their BMD as adults is generally normal.


Environment International | 2015

Exposure to phthalates, bisphenol A and metals in pregnancy and the association with impaired glucose tolerance and gestational diabetes mellitus: The MIREC study.

Gabriel D. Shapiro; Linda Dodds; Tye E. Arbuckle; Jillian Ashley-Martin; William D. Fraser; Mandy Fisher; Shayne Taback; E. Keely; Michèle Bouchard; Patricia Monnier; Renée Dallaire; As. Morisset; Adrienne S. Ettinger

BACKGROUND Studies from several countries report increases in rates of gestational diabetes mellitus (GDM) over recent decades. Exposure to environmental chemicals could contribute to this trend. OBJECTIVES To determine the associations between plasticisers and metals measured in early pregnancy with impaired glucose tolerance (IGT) and GDM in a Canadian pregnancy cohort. METHODS Women enrolled in the Maternal-Infant Research on Environmental Chemicals (MIREC) Study were included if they had a singleton delivery and did not have pre-existing diabetes. Eleven phthalate metabolites and total bisphenol A (BPA) were measured in first-trimester urine samples, and four metals (lead, cadmium, mercury and arsenic) were measured in first-trimester blood samples. IGT and GDM were assessed in accordance with standard guidelines by chart review. Chemical concentrations were grouped by quartiles, and associations with outcomes were examined using logistic regression with adjustment for maternal age, race, pre-pregnancy BMI, and education. Restricted cubic spline analysis was performed to help assess linearity and nature of any dose-response relationships. RESULTS Of 2001 women recruited into the MIREC cohort, 1274 met the inclusion criteria and had outcome data and biomonitoring data measured for at least one of the chemicals we examined. Elevated odds of GDM were observed in the highest quartile of arsenic exposure (OR = 3.7, 95% CI = 1.4-9.6) in the adjusted analyses. A significant dose-response relationship was observed in a cubic spline model between arsenic and odds of GDM (p < 0.01). No statistically significant associations were observed between phthalates or BPA or other metals with IGT or GDM. CONCLUSIONS Our findings add to the growing body of evidence supporting the role of maternal arsenic exposure as a risk factor for gestational diabetes.


Environmental Health | 2014

A birth cohort study to investigate the association between prenatal phthalate and bisphenol A exposures and fetal markers of metabolic dysfunction

Jillian Ashley-Martin; Linda Dodds; Tye E. Arbuckle; Adrienne S. Ettinger; Gabriel D. Shapiro; Mandy Fisher; Anne-Sophie Morisset; Shayne Taback; Maryse F. Bouchard; Patricia Monnier; Renée Dallaire; William D. Fraser

BackgroundObesity and type-2 diabetes are on the rise and in utero exposure to environmental contaminants is a suspected contributing factor. Our objective was to examine associations between prenatal exposure to potential endocrine disrupting chemicals and markers of fetal metabolic dysfunction.MethodsThe Maternal-Infant Research on Environmental Chemicals Study (MIREC) recruited 2001 women during the first trimester of pregnancy from 10 Canadian sites. First trimester maternal urine was measured for 11 phthalate metabolites and bisphenol A (BPA). Leptin and adioponectin measured in 1,363 available umbilical cord blood samples served as markers of metabolic function. Restricted cubic spline curves were used to assess the relationship between continuous measures of phthalate and BPA levels and cord blood adipokines. Polytomous logistic regression models were used to estimate odds ratios (OR) and 95% confidence intervals (CI) for the association between phthalates and BPA and both high (≥90th percentile) and low (≤10th percentile) fetal adiponectin and leptin, adjusting for confounding factors. Analyses were conducted for all subjects, overall, and separately by fetal sex.ResultsLeptin was significantly higher in female than male infants. We observed an inverse, non-linear relationship between BPA and adiponectin among males in the restricted cubic spline and linear regression analysis. Mono-(3-carboxypropyl) (MCPP) was associated with increased odds of high leptin among males in the polytomous logistic regression models (4th quartile OR = 3.5 95% CI: 1.1-11.6).ConclusionOur findings contribute to the growing body of evidence examining the influence of early life exposure on metabolic regulation and function. Associations between maternal exposure to chemicals and markers of metabolic function appear to be potentially sex specific. However, further investigation is required to determine whether in utero and childhood exposure to BPA and phthalates are associated with metabolic dysfunctions later in life.

Collaboration


Dive into the Shayne Taback's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge